A molecule that stops hunger without making you sick
En los márgenes del reino animal, donde las pitones sobreviven meses sin comer gracias a una silenciosa maestría metabólica, los científicos han encontrado una pista inesperada para uno de los problemas de salud más extendidos de nuestro tiempo. Investigadores de Stanford y la Universidad de Colorado Boulder han aislado el pTOS, la molécula que regula el apetito en estas serpientes, y han comprobado que suprime el hambre en ratones obesos sin los efectos secundarios que acompañan a fármacos como Ozempic. Es un recordatorio de que la evolución lleva millones de años resolviendo problemas que la medicina apenas empieza a formular.
- Los tratamientos actuales contra la obesidad funcionan, pero a un precio: náuseas crónicas, dolor abdominal y malestar digestivo que llevan a muchos pacientes a abandonarlos pese a su eficacia.
- El pTOS no acelera el metabolismo ni engaña al cuerpo para que queme más calorías — simplemente apaga el deseo de comer, actuando sobre un mecanismo distinto al de los fármacos GLP-1.
- En 28 días, los ratones tratados perdieron un 9% de su peso corporal sin que los investigadores observaran ninguna reacción adversa, una señal inicial llamativamente limpia.
- Con unos 100 millones de personas afectadas por obesidad en el mundo y un 15% de adultos diagnosticados solo en España, la urgencia de una alternativa tolerable no es retórica.
- El camino hacia los ensayos humanos es largo e incierto — dosis, metabolismo y seguridad a largo plazo siguen sin respuesta — pero el punto de partida es más prometedor de lo habitual.
Una pitón puede pasar año y medio sin comer. No porque le falte hambre, sino porque su cuerpo ha desarrollado una forma de apagarla: un interruptor metabólico que le permite entrar en un estado de profunda conservación energética. Investigadores de Stanford y la Universidad de Colorado Boulder han aislado la molécula responsable de ese mecanismo. La llaman pTOS, y creen que podría cambiar el tratamiento de la obesidad.
El equipo extrajo el pTOS y lo probó en ratones de laboratorio con obesidad inducida. En 28 días, los animales perdieron el 9% de su peso corporal. Comieron menos. Su apetito simplemente disminuyó. Y, de forma significativa, no se observaron reacciones adversas: ni náuseas, ni malestar digestivo, ni alteraciones metabólicas. Los ratones dejaron de tener hambre sin pagar ningún coste aparente.
Esto importa porque el estándar actual tiene un problema conocido. Fármacos como Ozempic, que imitan la hormona GLP-1, dominan el tratamiento de la obesidad y son eficaces, pero vienen acompañados de efectos secundarios tan pronunciados —náuseas crónicas, estreñimiento severo, dolor de estómago— que muchos pacientes los abandonan. La Organización Mundial de la Salud estima que unos 100 millones de personas viven con obesidad en el mundo; en España, el 15% de los adultos tiene ese diagnóstico.
Jonathan Long, profesor asociado de patología en Stanford, fue preciso al describir el mecanismo: el pTOS no acelera el metabolismo ni incrementa el gasto calórico. Actúa como supresor del apetito, modificando lo que el animal quiere comer, no cómo lo procesa. Esa distinción sugiere una vía de acción fundamentalmente diferente a la de los fármacos existentes, una que podría evitar el daño gastrointestinal que hace tan difícil tolerar los tratamientos GLP-1.
El camino del ratón al ser humano es largo e incierto. Los estudios animales no siempre se traducen. Dosis, metabolismo y seguridad a largo plazo siguen sin respuesta. Pero la señal inicial es clara. Si los resultados se mantienen en ensayos humanos, el pTOS podría convertirse en la alternativa que millones de personas con obesidad llevan tiempo esperando: un tratamiento que funcione sin el peso diario de las náuseas y el dolor. Lo que la evolución tardó millones de años en perfeccionar en una serpiente podría, quizás, convertirse en medicina moderna.
A python can go a year and a half without eating. Not because it lacks hunger, but because its body has evolved a way to turn hunger off—a metabolic switch that lets the animal slip into a state of profound metabolic conservation. Researchers at Stanford and the University of Colorado Boulder have now isolated the molecule responsible for that switch. They call it pTOS, and they believe it could reshape how medicine treats obesity.
The discovery emerged from a straightforward question: what if that python molecule could work in humans? The team extracted pTOS and tested it on laboratory mice bred to be obese. Within 28 days, the animals had shed 9 percent of their body weight. They ate less. Their appetite had simply diminished. Critically, the researchers observed no adverse reactions—no nausea, no digestive distress, no tremors or metabolic chaos. The mice just stopped being hungry.
This matters because the current standard of care has a problem. Drugs like Ozempic, which mimic the hormone GLP-1, have become the dominant treatment for obesity. They work. But they come with a cost. Patients report chronic nausea, severe constipation, stomach pain—side effects so pronounced that some people stop taking the medication despite its effectiveness. According to the World Health Organization, roughly 100 million people worldwide live with obesity. In Spain alone, 15 percent of adults carry an obesity diagnosis. The need for a better option is not theoretical.
Jonathan Long, an associate professor of pathology at Stanford, was careful to clarify what pTOS actually does. It is not a metabolic accelerant. It does not trick the body into burning more calories. Instead, it acts as an appetite suppressant—it changes what the animal wants to eat, not how the animal processes food. That distinction matters. It suggests a mechanism fundamentally different from existing drugs, one that might avoid the gastrointestinal havoc that makes GLP-1 treatments so difficult to tolerate.
Leslie Leinwand, a biologist at the University of Colorado Boulder, framed the finding in direct terms: the team had discovered an appetite suppressor that worked in animal models without the side effect burden of current medications. The word "discovered" is precise. This was not an invention. It was an extraction—taking something that evolution had already solved and asking whether it could solve the same problem in a different species.
The path from mouse to human is long and uncertain. Animal studies often do not translate. Dosing, metabolism, long-term safety—all of these remain unknown. But the initial signal is clean. No adverse reactions in the test animals. Meaningful weight loss. An appetite mechanism that appears to operate independently of the systems that GLP-1 drugs target. If those results hold up in human trials, pTOS could become the alternative that millions of people with obesity have been waiting for—a treatment that works without the daily burden of nausea and digestive pain. The next phase will tell whether a python's ancient metabolic trick can become modern medicine.
Citações Notáveis
We discovered an appetite suppressant that works in mice without the side effects that come with GLP-1 drugs— Leslie Leinwand, biologist at University of Colorado Boulder
The molecule regulated appetite and eating habits in the mice, not their energy expenditure— Jonathan Long, associate professor of pathology at Stanford University
A Conversa do Hearth Outra perspectiva sobre a história
Why does a python's ability to fast matter to someone trying to lose weight?
Because the python's body has solved a problem we haven't: how to suppress hunger without breaking the system. When we give people Ozempic, we're forcing their bodies to feel sick as a side effect of appetite loss. The python just... stops being hungry. That's a different mechanism entirely.
So pTOS isn't making the mice burn more calories?
No. That's the crucial part. It's not speeding up metabolism. It's changing the signal that says "eat." That's why there's no nausea, no stomach pain. You're not forcing the body to work harder. You're just quieting one voice.
The mice lost 9 percent in a month. Is that realistic for humans?
We don't know yet. Animal studies are clean because the variables are controlled. Real humans have stress, sleep deprivation, different genetics. But the fact that it worked at all without side effects is the signal worth watching.
What happens if this fails in human trials?
Then we're back where we started—Ozempic and its cousins, nausea and all. But the researchers wouldn't have published if they didn't think the mechanism was sound. They're betting on the biology.
How long until someone could actually take this?
Years, probably. Phase one safety trials, then efficacy trials, then regulatory approval. But for people suffering through Ozempic's side effects right now, knowing there's something in the pipeline changes the calculus.